Literature DB >> 30159745

Expectations and fear of diabetes-related long-term complications in people with type 2 diabetes at primary care level.

Nadine Kuniss1,2, Michael Freyer3, Nicolle Müller4, Volker Kielstein5, Ulrich A Müller4.   

Abstract

AIMS: The quality report of patients enrolled in the disease management programmes of North Rhine Westphalia 2016 showed prevalence of long-term complications in diabetes type 2: neuropathy 24.2%, nephropathy 12.5%, retinopathy 8.2%. The aim of this study was to assess expectations and fear of diabetes-related long-term complications in people with diabetes type 2.
METHODS: We assessed expectations and fear of diabetes-related complications in 104 people with diabetes type 2 (age 67.0J, diabetes duration 6.6J, HbA1c 6.6%/48.6 mmol/mol, neuropathy 20.2%, nephropathy 11.5%, retinopathy 1.9%) in an outpatient healthcare centre at primary care level. Fear of diabetes-related complications was assessed using the "Fear of Complications Questionnaire" (FCQ) with a range of 0-45 points (≥ 30 means clinically meaningful fear, higher scores imply higher level of fear). Furthermore, study participants estimated general and personal risk of suffering from diabetes-related long-term complications after 10 years of diabetes duration on a scale of 0-100%.
RESULTS: Mean FCQ score was 22.9 ± 11.5. 34/104 participants (32.7%) scored ≥ 30 points and thus had great fear. Participants estimated general risk of suffering from diabetes-related complications after 10 years of diabetes duration on 55.1% and personal risk on 46.0%. Risk of diabetes-related complications scoring highest was impaired circulation of lower limb (62.1%), eye complications (57.3%) and kidney complications (54.7%).
CONCLUSION: Prevalence of diabetes-related long-term complications was overestimated in people with diabetes type 2. Approximately one third of the participants showed even great fear. Patient expectation and fear about diabetes-associated complications did not correspondent with data on clinical reality.

Entities:  

Keywords:  Diabetes-related complications; FCQ; Fear of complications

Mesh:

Substances:

Year:  2018        PMID: 30159745     DOI: 10.1007/s00592-018-1217-9

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  6 in total

Review 1.  Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond.

Authors:  Sejal Lahoti; Mouhamed Nashawi; Omar Sheikh; David Massop; Mahnoor Mir; Robert Chilton
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-18

2.  What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.

Authors:  W David Strain; Carmen Tsang; Michael Hurst; Phil McEwan; Minesh Unadkat; Simon Meadowcroft; Richard Shardlow; Marc Evans
Journal:  Diabetes Ther       Date:  2020-05-18       Impact factor: 2.945

3.  Disclosure of New Type 2 Diabetes Diagnoses to Younger Adults: a Qualitative Study.

Authors:  Anjali Gopalan; Maruta A Blatchins; Andrea Altschuler; Pranita Mishra; Issa Fakhouri; Richard W Grant
Journal:  J Gen Intern Med       Date:  2021-01-26       Impact factor: 5.128

4.  Factors Affecting Compliance with Diabetic Retinopathy Screening: A Qualitative Study Comparing English and Spanish Speakers.

Authors:  Sharon M Hudson; Bobeck S Modjtahedi; Danielle Altman; Jennifer J Jimenez; Tiffany Q Luong; Donald S Fong
Journal:  Clin Ophthalmol       Date:  2022-04-04

Review 5.  New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors.

Authors:  Prabhakar Busa; Yaswanth Kuthati; Niancih Huang; Chih-Shung Wong
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 6.  The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes.

Authors:  Habib Yaribeygi; Farin Rashid Farrokhi; Mohammed Altigani Abdalla; Thozhukat Sathyapalan; Maciej Banach; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-06-30       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.